Frontiers in Immunology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-08-28 Cassie2696 来自上海

投稿三周了，还没分配编辑👿

44 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-07-29 ZeBoJiang 来自广东省

快三个月了，还是没有回审稿意见呢，好慢

57 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-10-21 ms1000002061166836 来自北京

审稿速度:1.0 | 投稿命中率:25.0
经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不

4 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2024-10-16 ms5000000269186861

审稿速度:3.0
经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。
15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office.
12 Oct 2024 Review of Review Editor 1 finalized.
10 Oct 2024 Review of Review Editor 2 finalized.
05 Oct 2024 Corresponding Author re-submitted manuscript
28 Aug 2024 Associate Editor posted new comments in the Editor tab.
23 Aug 2024 Interactive review forum activated automatically.
21 Jul 2024 Corresponding Author submitted manuscript.

56 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-10-14 ms5000001712628444 来自北京

偏重的研究方向：免疫;肿瘤
经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢

16 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-04-27 ms4000000257993669 来自重庆

审稿速度:1.0
偏重的研究方向：免疫调控
经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息

82 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-10-02 suguoqing.my265 来自吉林省

偏重的研究方向：免疫;炎症;综述
经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的

23 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-09-15 匿名用户

Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）

36 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-08-27 ms3000001615450359 来自云南省

偏重的研究方向：免疫;肿瘤
经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回#Frontiers in immunology#

47 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2279012, encodeId=9c0e22e901280, content=投稿三周了，还没分配编辑👿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/03/10/9fdf15d0a290dd06fdba819b71088a42.jpg, createdBy=b6ef2564439, createdName=Cassie2696, createdTime=Thu Aug 28 10:02:58 CST 2025, time=2025-08-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2275311, encodeId=2ca822e53116c, content=快三个月了，还是没有回审稿意见呢，好慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45525539852, createdName=ZeBoJiang, createdTime=Tue Jul 29 14:52:02 CST 2025, time=2025-07-29, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2285564, encodeId=8de0228556451, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投了一篇文章，给了小修，然后修改后直接给拒了，说是没按照要求修改，想申诉可以不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e7a9363000, createdName=ms1000002061166836, createdTime=Tue Oct 21 16:16:48 CST 2025, time=2025-10-21, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2231217, encodeId=a453223121e3d, content=审稿速度:3.0 经验分享：历时三个月，两个审稿人同意接受，最后编辑部FV阶段要求再提供WB未裁剪条带，按要求提交后马上拒稿，拒稿原因：Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.Following our data request, some issues were identified regarding the original images and/or data provided. 也没说具体为什么数据不合要求就拒了，发邮件询问也不回复。一开始也提供原始条带并审查通过，为什么初始审查阶段不拒稿。修稿花费了大量的时间经历，真是浪费宝贵时间，而且不明不白。 15 Oct 2024 Article rejected by Editorial Office Frontiers in Immunology Editorial Office. 12 Oct 2024 Review of Review Editor 1 finalized. 10 Oct 2024 Review of Review Editor 2 finalized. 05 Oct 2024 Corresponding Author re-submitted manuscript 28 Aug 2024 Associate Editor posted new comments in the Editor tab. 23 Aug 2024 Interactive review forum activated automatically. 21 Jul 2024 Corresponding Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc876407283, createdName=ms5000000269186861, createdTime=Wed Oct 16 15:58:09 CST 2024, time=2024-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2284754, encodeId=fc7a2284e5409, content=偏重的研究方向：免疫;肿瘤 经验分享：投稿十天了，还在Editorial Assignment，但我看下面有个编辑了已经，这是什么意思呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c73c5484158, createdName=ms5000001712628444, createdTime=Tue Oct 14 17:46:36 CST 2025, time=2025-10-14, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2262462, encodeId=a5ba2262462f5, content=审稿速度:1.0 偏重的研究方向：免疫调控 经验分享：问下大家投稿到现在已经快三周了，还在EA阶段，没有任何消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e9679589603, createdName=ms4000000257993669, createdTime=Sun Apr 27 10:19:58 CST 2025, time=2025-04-27, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2283434, encodeId=bf6d22834346d, content=偏重的研究方向：免疫;炎症;综述 经验分享：投稿速度的主要决定因素是副主编与审稿人，编辑办公室小律是很高的，经历了最快的一次审稿流程。 2025.7.23 投稿 2025.7.24 分配编辑 2025.7.26进入外审 2025.7.29 第一份审稿提交 2025.7.30 第二份审稿提交 2025.7.30 返修，一个大修、一个小修 2025.8.7 返修回稿，当天接受只要副主编和审稿人给力，速度杠杠的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3b21498451, createdName=suguoqing.my265, createdTime=Thu Oct 02 05:47:21 CST 2025, time=2025-10-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2281296, encodeId=506a228129641, content=Frontiers 的期刊要求对主要基于生物信息学分析、公共数据计算研究或孟德尔随机化研究结果的手稿进行强有力的验证。可接受的验证形式包括： - 独立的临床或患者队列，或 - 生物学验证，体外或体内，或 - 多数据库查询（仅限文献计量研究）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=匿名用户, createdTime=Mon Sep 15 09:43:13 CST 2025, time=2025-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2278952, encodeId=648f22e8952ad, content=偏重的研究方向：免疫;肿瘤 经验分享：大佬们，想咨询一下投稿初审就被拒了，然后鬼使神差的填了申诉表格，但是快一周了回执信息也没有，现在也不知道申诉是不是提交成功了，也不敢投下一个期刊，这种该怎么办…发邮件了也不回<a href='/topic/show?id=8eb91049e349' target=_blank style='color:#2F92EE;'>#Frontiers in immunology#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=104973, encryptionId=8eb91049e349, topicName=Frontiers in immunology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eada8649700, createdName=ms3000001615450359, createdTime=Wed Aug 27 16:08:39 CST 2025, time=2025-08-27, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2279441, encodeId=29a522e9441a4, content=一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。 影响因子在5-8.8之间，中科院分区为医学2区。 审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。 对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms7000002977722171, createdTime=Sun Aug 31 16:18:53 CST 2025, time=2025-08-31, status=1, ipAttribution=上海)]

2025-08-31 ms7000002977722171 来自上海

一本在免疫学领域具有较高影响力的国际期刊，属于SCI收录期刊。
影响因子在5-8.8之间，中科院分区为医学2区。
审稿周期约14周。投稿时需准备完整的稿件、图表、摘要等材料，并注意语言表达和数据的准确性。
对论文质量要求较高，但对高质量研究的接受度较高，是免疫学领域的重要发表平台。

44 0 举报

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务